The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol
Recruitment status was: Not yet recruiting
The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols.
Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen.
The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate.
The patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy.
The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors.
|Embryo's Genetic and Chromosomal Quality||Drug: ghrh antagonist (cetrotide/orgalutran) Drug: gnrh agonist (suprefact)||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
- The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol [ Time Frame: one year ]difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||September 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Active Comparator: short protocol
gnrh agonist versus gnrh antagonist
Drug: ghrh antagonist (cetrotide/orgalutran)
cetrotide/orgalutran 0.25 mg
|Active Comparator: long protocol||
Drug: gnrh agonist (suprefact)
suprefact 5.5 ml
Please refer to this study by its ClinicalTrials.gov identifier: NCT01636505
|European Hospital||Not yet recruiting|
|Rome, Italy, 00148|
|Contact: Ermanno Greco, MD 06-65975643 firstname.lastname@example.org|
|Principal Investigator: Ermanno greco, MD|